128 related articles for article (PubMed ID: 30827083)
1. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma.
Wolosz D; Walczak A; Szparecki G; Dwojak M; Winiarska M; Wolinska E; Gornicka B
Eur J Histochem; 2019 Feb; 63(1):. PubMed ID: 30827083
[TBL] [Abstract][Full Text] [Related]
2. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain.
Ng DC; Chan SF; Kok KH; Yam JW; Ching YP; Ng IO; Jin DY
FEBS Lett; 2006 Jan; 580(1):191-8. PubMed ID: 16364308
[TBL] [Abstract][Full Text] [Related]
4. High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC.
Sun L; Sun J; Song JD
Mol Med Rep; 2019 Jun; 19(6):4881-4889. PubMed ID: 31059015
[TBL] [Abstract][Full Text] [Related]
5. DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.
Wang D; Qian X; Rajaram M; Durkin ME; Lowy DR
Oncotarget; 2016 Jul; 7(29):45144-45157. PubMed ID: 27174913
[TBL] [Abstract][Full Text] [Related]
6. The Role of Tumor Suppressor DLC-1: Far From Clear.
Liu X; Pan YJ; Zheng JN; Pei DS
Anticancer Agents Med Chem; 2017; 17(7):896-901. PubMed ID: 27604574
[TBL] [Abstract][Full Text] [Related]
7. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
Wong CM; Lee JM; Ching YP; Jin DY; Ng IO
Cancer Res; 2003 Nov; 63(22):7646-51. PubMed ID: 14633684
[TBL] [Abstract][Full Text] [Related]
9. Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma.
Xiaorong L; Wei W; Liyuan Q; Kaiyan Y
BMC Cancer; 2008 Jul; 8():205. PubMed ID: 18651974
[TBL] [Abstract][Full Text] [Related]
10. The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1.
Muehlich S; Hampl V; Khalid S; Singer S; Frank N; Breuhahn K; Gudermann T; Prywes R
Oncogene; 2012 Aug; 31(35):3913-23. PubMed ID: 22139079
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
Ullmannova V; Popescu NC
Int J Oncol; 2006 Nov; 29(5):1127-32. PubMed ID: 17016643
[TBL] [Abstract][Full Text] [Related]
12. The intracellular stability of DLC1 is regulated by the 26S proteasome in human hepatocellular carcinoma cell line Hep3B.
Luo HW; Luo QP; Yuan Y; Zhu XY; Huang SF; Peng Z; Li CL; Huang ZG; Feng WL
Biochem Biophys Res Commun; 2011 Jan; 404(1):279-83. PubMed ID: 21130076
[TBL] [Abstract][Full Text] [Related]
13. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
14. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
Ko FC; Yeung YS; Wong CM; Chan LK; Poon RT; Ng IO; Yam JW
Liver Int; 2010 Jan; 30(1):139-48. PubMed ID: 19874489
[TBL] [Abstract][Full Text] [Related]
15. Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway.
Leung TH; Yam JW; Chan LK; Ching YP; Ng IO
Liver Int; 2010 Oct; 30(9):1315-23. PubMed ID: 20629949
[TBL] [Abstract][Full Text] [Related]
16. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
Kim TY; Lee JW; Kim HP; Jong HS; Kim TY; Jung M; Bang YJ
Biochem Biophys Res Commun; 2007 Mar; 355(1):72-7. PubMed ID: 17292327
[TBL] [Abstract][Full Text] [Related]
17. The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory stimuli.
Chan FK; Chung SS; Ng IO; Chung SK
Neurosignals; 2012; 20(2):112-26. PubMed ID: 22204965
[TBL] [Abstract][Full Text] [Related]
18. DLC1: a significant GAP in the cancer genome.
Lahoz A; Hall A
Genes Dev; 2008 Jul; 22(13):1724-30. PubMed ID: 18593873
[TBL] [Abstract][Full Text] [Related]
19. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity.
Leung TH; Ching YP; Yam JW; Wong CM; Yau TO; Jin DY; Ng IO
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15207-12. PubMed ID: 16217026
[TBL] [Abstract][Full Text] [Related]
20. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.
Ko FC; Chan LK; Tung EK; Lowe SW; Ng IO; Yam JW
Gastroenterology; 2010 Oct; 139(4):1397-407. PubMed ID: 20600027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
